Vanqua Bio Inc. has divulged C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections and cardiovascular, inflammatory and neurological disorders.
Benevolentai Cambridge Ltd. has synthesized retinoid acid receptor α (RARα) and β (RARβ) agonists reported to be useful for the treatment of cancer and amyotrophic lateral sclerosis (ALS).
Global Health Drug Discovery Institute has disclosed N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of cancer and viral infections.
Richmond Hill, N.Y.-based Ihealthscreen Inc. reported the granting of a patent from the USPTO for automated systems for predicting and detecting the onset of glaucoma.
Prelude Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety. They are described as potentially useful for the treatment of cancer.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified pyrimidine-containing polycyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Cambridge Enterprise Ltd. has synthesized casein kinase II isoform α (CK2α) inhibitors reported to be useful for the treatment of cancer, viral infection, diabetes, ischemia, neurodegeneration, circadian rhythm disorders, vascular disorders and inflammatory disorders.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has disclosed molecular glue degraders comprising cereblon (CRBN) ligands acting as DNA-binding protein Ikaros (IKZF1) or zinc finger protein Aiolos (IKZF3) degradation inducers reported to be useful for the treatment of cancer, autoimmune diseases, diabetes, infections, septic shock and more.
RSS
